Conditional Probability of Survival in Patients with Glioblastoma Multiforme in the Temozolomide Treatment Era

Authors:
  • ZLZ. Lwin
    Z. Lwin
  • HJH. Jiang
    H. Jiang
  • CCC. Chung
    C. Chung
  • BMB. Millar
    B. Millar
  • NLN. Laperriere
    N. Laperriere
  • WMW. Mason
    W. Mason
  • GLG. Lombardi
    G. Lombardi
  • GCG. Corona
    G. Corona
  • PFP. Farina
    P. Farina
  • FZF. Zustovich
    F. Zustovich
  • RBR. Bertorelle
    R. Bertorelle

Abstract
Glioblastoma multiforme (GBM) is the most aggressive of gliomas. With standard treatment consisting of surgery followed by radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ), median survival is approximately 14.6 mo. These estimates are not as informative to patients (pts) who have survived for some time after diagnosis. Aim: To retrospectively review outcomes and report conditional probability estimates in the TMZ treatment era of pts who presented to a multidisciplinary team at the tertiary referral center PrincessMargaretHospital, Toronto, with a diagnosis of GBM.